Two complement receptor one alleles have opposing associations with cerebral malaria and interact with α+thalassaemia

  1. D Herbert Opi
  2. Olivia Swann  Is a corresponding author
  3. Alexander Macharia
  4. Sophie Uyoga
  5. Gavin Band
  6. Carolyne M Ndila
  7. Ewen Harrison
  8. Mahamadou A Thera
  9. Abdoulaye K Kone
  10. Dapa A Diallo
  11. Ogobara K Doumbo
  12. Kirsten E Lyke
  13. Christopher Plowe
  14. Joann M Moulds
  15. Mohammed Shebbe
  16. Neema Mturi
  17. Norbert Peshu
  18. Kathryn Maitland
  19. Ahmed Raza
  20. Dominic P Kwiatkowski
  21. Kirk A Rockett
  22. Thomas Williams
  23. J Alexandra Rowe
  1. Kenya Medical Research Institute-Wellcome Trust Research Programme, Kenya
  2. University of Edinburgh, United Kingdom
  3. University of Oxford, United Kingdom
  4. University of Bamako, Mali
  5. University of Maryland, United States
  6. Lifeshare Blood Centers, United States

Abstract

Malaria has been a major driving force in the evolution of the human genome. In sub-Saharan African populations, two neighbouring polymorphisms in the Complement Receptor One (CR1) gene, named Sl2 and McCb, occur at high frequencies, consistent with selection by malaria. Previous studies have been inconclusive. Using a large case-control study of severe malaria in Kenyan children and statistical models adjusted for confounders, we estimate the relationship between Sl2 and McCb and malaria phenotypes, and find they have opposing associations. The Sl2 polymorphism is associated with markedly reduced odds of cerebral malaria and death, while the McCb polymorphism is associated with increased odds of cerebral malaria. We also identify an apparent interaction between Sl2 and α+thalassaemia, with the protective association of Sl2 greatest in children with normal α-globin. The complex relationship between these three mutations may explain previous conflicting findings, highlighting the importance of considering genetic interactions in disease-association studies.

Data availability

The following previously published data sets were used
    1. Rockett K
    2. Clarke GM
    3. Fitzpatrick K
    4. Hubbart C
    5. Jeffrys AE
    6. Rowlands K
    7. et al
    (2014) MalariaGEN Consortial Project 1
    Application for access to data: https://www.malariagen.net/data/terms-use/human-gwas-data.

Article and author information

Author details

  1. D Herbert Opi

    Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya
    Competing interests
    The authors declare that no competing interests exist.
  2. Olivia Swann

    Centre for Immunity, Infection and Evolution, University of Edinburgh, Edinburgh, United Kingdom
    For correspondence
    Olivia.Swann@ed.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7386-2849
  3. Alexander Macharia

    Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya
    Competing interests
    The authors declare that no competing interests exist.
  4. Sophie Uyoga

    Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya
    Competing interests
    The authors declare that no competing interests exist.
  5. Gavin Band

    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  6. Carolyne M Ndila

    Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya
    Competing interests
    The authors declare that no competing interests exist.
  7. Ewen Harrison

    Centre for Immunity, Infection and Evolution, University of Edinburgh, Edinburgh, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  8. Mahamadou A Thera

    Malaria Research and Training Centre, University of Bamako, Bamako, Mali
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2679-035X
  9. Abdoulaye K Kone

    Malaria Research and Training Centre, University of Bamako, Bamako, Mali
    Competing interests
    The authors declare that no competing interests exist.
  10. Dapa A Diallo

    Malaria Research and Training Centre, University of Bamako, Bamako, Mali
    Competing interests
    The authors declare that no competing interests exist.
  11. Ogobara K Doumbo

    Malaria Research and Training Centre, University of Bamako, Bamako, Mali
    Competing interests
    The authors declare that no competing interests exist.
  12. Kirsten E Lyke

    Division of Malaria Research, Institute for Global Health, University of Maryland, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Christopher Plowe

    Division of Malaria Research, Institute for Global Health, University of Maryland, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Joann M Moulds

    Lifeshare Blood Centers, Shreveport, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. Mohammed Shebbe

    Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya
    Competing interests
    The authors declare that no competing interests exist.
  16. Neema Mturi

    Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya
    Competing interests
    The authors declare that no competing interests exist.
  17. Norbert Peshu

    Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya
    Competing interests
    The authors declare that no competing interests exist.
  18. Kathryn Maitland

    Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya
    Competing interests
    The authors declare that no competing interests exist.
  19. Ahmed Raza

    Centre for Immunity, Infection and Evolution, University of Edinburgh, Edinburgh, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  20. Dominic P Kwiatkowski

    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  21. Kirk A Rockett

    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6369-9299
  22. Thomas Williams

    Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya
    Competing interests
    The authors declare that no competing interests exist.
  23. J Alexandra Rowe

    Centre for Immunity, Infection and Evolution, University of Edinburgh, Edinburgh, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7702-1892

Funding

Wellcome Trust (Senior Research Fellowship 091758)

  • Thomas Williams

Wellcome Trust (Senior Research Fellowship202800)

  • Thomas Williams

Wellcome Trust (Senior Research Fellowship084226)

  • J Alexandra Rowe

Wellcome Trust (203077)

  • D Herbert Opi

Wellcome Trust (84538)

  • D Herbert Opi

Wellcome Trust (101910/Z/13/Z)

  • Olivia Swann

Medical Research Council (G19/9)

  • Dominic P Kwiatkowski

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: This work involved analysing blood samples from patients with malaria and from healthy controls. Written informed consent was obtained from the parents or legal guardians of all participants. The Kenyan studies received ethical approval from the Kenya Medical Research Institute National Ethical Review Committee (approval number SCC1192 for the case-control study and SCC3149 for the longitudinal cohort study), and the Malian studies received ethical approval from the University of Bamako and the University of Maryland (approval number #0899139), and were conducted in accordance with the Declaration of Helsinki.

Copyright

© 2018, Opi et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,685
    views
  • 212
    downloads
  • 24
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. D Herbert Opi
  2. Olivia Swann
  3. Alexander Macharia
  4. Sophie Uyoga
  5. Gavin Band
  6. Carolyne M Ndila
  7. Ewen Harrison
  8. Mahamadou A Thera
  9. Abdoulaye K Kone
  10. Dapa A Diallo
  11. Ogobara K Doumbo
  12. Kirsten E Lyke
  13. Christopher Plowe
  14. Joann M Moulds
  15. Mohammed Shebbe
  16. Neema Mturi
  17. Norbert Peshu
  18. Kathryn Maitland
  19. Ahmed Raza
  20. Dominic P Kwiatkowski
  21. Kirk A Rockett
  22. Thomas Williams
  23. J Alexandra Rowe
(2018)
Two complement receptor one alleles have opposing associations with cerebral malaria and interact with α+thalassaemia
eLife 7:e31579.
https://doi.org/10.7554/eLife.31579

Share this article

https://doi.org/10.7554/eLife.31579

Further reading

    1. Epidemiology and Global Health
    2. Microbiology and Infectious Disease
    Bo Zheng, Bronner P Gonçalves ... Caoyi Xue
    Research Article

    Background:

    In many settings, a large fraction of the population has both been vaccinated against and infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Hence, quantifying the protection provided by post-infection vaccination has become critical for policy. We aimed to estimate the protective effect against SARS-CoV-2 reinfection of an additional vaccine dose after an initial Omicron variant infection.

    Methods:

    We report a retrospective, population-based cohort study performed in Shanghai, China, using electronic databases with information on SARS-CoV-2 infections and vaccination history. We compared reinfection incidence by post-infection vaccination status in individuals initially infected during the April–May 2022 Omicron variant surge in Shanghai and who had been vaccinated before that period. Cox models were fit to estimate adjusted hazard ratios (aHRs).

    Results:

    275,896 individuals were diagnosed with real-time polymerase chain reaction-confirmed SARS-CoV-2 infection in April–May 2022; 199,312/275,896 were included in analyses on the effect of a post-infection vaccine dose. Post-infection vaccination provided protection against reinfection (aHR 0.82; 95% confidence interval 0.79–0.85). For patients who had received one, two, or three vaccine doses before their first infection, hazard ratios for the post-infection vaccination effect were 0.84 (0.76–0.93), 0.87 (0.83–0.90), and 0.96 (0.74–1.23), respectively. Post-infection vaccination within 30 and 90 days before the second Omicron wave provided different degrees of protection (in aHR): 0.51 (0.44–0.58) and 0.67 (0.61–0.74), respectively. Moreover, for all vaccine types, but to different extents, a post-infection dose given to individuals who were fully vaccinated before first infection was protective.

    Conclusions:

    In previously vaccinated and infected individuals, an additional vaccine dose provided protection against Omicron variant reinfection. These observations will inform future policy decisions on COVID-19 vaccination in China and other countries.

    Funding:

    This study was funded the Key Discipline Program of Pudong New Area Health System (PWZxk2022-25), the Development and Application of Intelligent Epidemic Surveillance and AI Analysis System (21002411400), the Shanghai Public Health System Construction (GWVI-11.2-XD08), the Shanghai Health Commission Key Disciplines (GWVI-11.1-02), the Shanghai Health Commission Clinical Research Program (20214Y0020), the Shanghai Natural Science Foundation (22ZR1414600), and the Shanghai Young Health Talents Program (2022YQ076).

    1. Epidemiology and Global Health
    Marina Padilha, Victor Nahuel Keller ... Gilberto Kac
    Research Article Updated

    Background:

    The role of circulating metabolites on child development is understudied. We investigated associations between children’s serum metabolome and early childhood development (ECD).

    Methods:

    Untargeted metabolomics was performed on serum samples of 5004 children aged 6–59 months, a subset of participants from the Brazilian National Survey on Child Nutrition (ENANI-2019). ECD was assessed using the Survey of Well-being of Young Children’s milestones questionnaire. The graded response model was used to estimate developmental age. Developmental quotient (DQ) was calculated as the developmental age divided by chronological age. Partial least square regression selected metabolites with a variable importance projection ≥1. The interaction between significant metabolites and the child’s age was tested.

    Results:

    Twenty-eight top-ranked metabolites were included in linear regression models adjusted for the child’s nutritional status, diet quality, and infant age. Cresol sulfate (β=–0.07; adjusted-p <0.001), hippuric acid (β=–0.06; adjusted-p <0.001), phenylacetylglutamine (β=–0.06; adjusted-p <0.001), and trimethylamine-N-oxide (β=–0.05; adjusted-p=0.002) showed inverse associations with DQ. We observed opposite directions in the association of DQ for creatinine (for children aged –1 SD: β=–0.05; pP=0.01;+1 SD: β=0.05; p=0.02) and methylhistidine (–1 SD: β = - 0.04; p=0.04;+1 SD: β=0.04; p=0.03).

    Conclusions:

    Serum biomarkers, including dietary and microbial-derived metabolites involved in the gut-brain axis, may potentially be used to track children at risk for developmental delays.

    Funding:

    Supported by the Brazilian Ministry of Health and the Brazilian National Research Council.